PUBLISHER: The Business Research Company | PRODUCT CODE: 1889548
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889548
Rabbit monoclonal antibody is a highly specific antibody produced from a single clone of rabbit B cells. It demonstrates strong affinity and can recognize small or conserved epitopes that are often difficult for mouse antibodies to detect. It is used for accurate detection, quantification, or targeting of specific proteins in research, diagnostic, and therapeutic applications.
The main types of rabbit monoclonal antibody include immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin D (IgD). Immunoglobulin G (IgG) rabbit monoclonal antibody is a high affinity, antigen specific antibody derived from rabbit B cells and represents the predominant immunoglobulin class used for precise detection, diagnosis, and therapeutic purposes. It is applied in diagnostics, therapeutics, research, drug discovery, and immunohistochemistry, serving end users such as pharmaceutical companies, academic and research institutions, diagnostic laboratories, contract research organizations, and biotechnology companies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The rabbit monoclonal antibody market research report is one of a series of new reports from The Business Research Company that provides rabbit monoclonal antibody market statistics, including rabbit monoclonal antibody industry global market size, regional shares, competitors with a rabbit monoclonal antibody market share, detailed rabbit monoclonal antibody market segments, market trends and opportunities, and any further data you may need to thrive in the rabbit monoclonal antibody industry. This rabbit monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rabbit monoclonal antibody market size has grown rapidly in recent years. It will grow from $0.83 billion in 2024 to $0.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing demand for targeted therapies, growing adoption in diagnostic applications, rising government funding for antibody based studies, and growing application in immunology and oncology.
The rabbit monoclonal antibody market size is expected to see strong growth in the next few years. It will grow to $1.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising adoption in oncology and immunology, growing biopharmaceutical pipeline expansion, increasing collaborations between biotech companies, and rising demand for high specificity therapeutic agents. Major trends in the forecast period include technological advancements in antibody engineering, innovations in bispecific and multispecific antibodies, development of fully human rabbit monoclonal antibodies, research and development in next generation antibody platforms, and integration of AI and automation in antibody discovery.
The rising prevalence of chronic diseases is expected to drive the growth of the rabbit monoclonal antibody market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical care. The increasing prevalence of these diseases is partly due to sedentary lifestyles, as extended periods of sitting and low physical activity increase the risk of conditions such as heart disease and diabetes. Rabbit monoclonal antibodies support chronic disease treatment by providing highly specific and high-affinity targeting of disease-associated proteins. They improve therapeutic precision, minimize off-target effects, and enhance treatment efficacy, contributing to better patient outcomes and more efficient drug development. For example, in June 2024, according to the National Health Service, a UK based government department, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, reflecting an 18 percent increase from 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is driving the expansion of the rabbit monoclonal antibody market.
Major companies in the rabbit monoclonal antibody market are developing advanced platforms such as species-specific antibody development to improve therapeutic efficacy, enhance target specificity, and reduce immunogenicity. Species-specific antibody development involves using distinct animal immune systems to produce antibodies with unique binding characteristics and high affinity for challenging drug targets. In September 2024, ImmunoPrecise Antibodies Ltd., a Canada based AI-driven biotherapeutic research and technology company, reported significant progress in its rabbit antibody platforms. The species-specific antibody demonstrated notable clinical advancements through its B Cell Select platform integrated with LENSai artificial intelligence technology for automated antibody discovery and optimization. This combination of automation and AI-driven analytics rapidly identifies high-affinity rabbit monoclonal antibodies while maintaining native structures. The approach improves clinical translation efficiency, accelerates target validation, shortens development timelines, and enhances reproducibility in therapeutic antibody programs.
In September 2024, Leinco Technologies Inc., a US based biotechnology company, acquired QED Biosciences Inc. for an undisclosed amount. Through this acquisition, Leinco Technologies aims to expand its antibody capabilities and strengthen its presence in the research, diagnostic, and rabbit monoclonal antibody markets. QED Biosciences Inc. is a US based biotechnology company specializing in the development and supply of high-quality rabbit monoclonal antibodies.
Major companies operating in the rabbit monoclonal antibody market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Avantor Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Elabscience Biotechnology Inc., GenScript Biotech Corporation, Takara Bio Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Bioss Antibodies Inc., Cell Signaling Technology Inc., MyBioSource Inc., Boster Biological Technology Co. Ltd., GeneTex Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., AvantGen Inc., ImmunoWay Biotechnology Company
North America was the largest region in the rabbit monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rabbit monoclonal antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rabbit monoclonal antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rabbit monoclonal antibody market consists of sales of recombinant rabbit monoclonal antibodies, polyclonal-to-monoclonal conversion antibodies, isotype control antibodies, and phospho-specific rabbit monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rabbit Monoclonal Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rabbit monoclonal antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for rabbit monoclonal antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rabbit monoclonal antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.